Dermata Therapeutics Earnings Estimate

DRMA -  USA Stock  

USD 1.68  0.17  11.26%

Many public companies, such as Dermata Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Dermata Therapeutics' earnings estimates, investors can diagnose different trends across Dermata Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Dermata Therapeutics is projected to generate -2.39 in earnings per share on the 31st of December 2021. Dermata Therapeutics earnings estimates module stress-tests analyst consensus about projected Dermata Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Investing Opportunities.

Dermata Earnings Estimates 

 
Refresh

Dermata Therapeutics Earnings Estimation Breakdown

Calculation of earning per share of Dermata Therapeutics is based on official Zacks consensus of 1 analysts regarding Dermata Therapeutics future annual earnings. Given the historical accuracy of 0.0%, the future earnings per share of Dermata Therapeutics is estimated to be -2.39 with the lowest and highest values of -2.39 and -2.39, respectively. Please note that this consensus of annual earnings estimates for Dermata Therapeutics is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
-3.09
19th of January 2022
-2.39
Lowest
Estimated EPS
-2.39
-2.39
Highest

Dermata Therapeutics Earnings Projection Consensus

Suppose the current estimates of Dermata Therapeutics' value are higher than the current market price of the Dermata Therapeutics stock. In this case, investors may conclude that Dermata Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dermata Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

1

0.0%

-3.092

-2.39

Dermata Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Dermata Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dermata Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Dermata Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Dermata Therapeutics Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Dermata Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dermata Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Dermata Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Dermata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-15
2021-09-30-0.25-0.86-0.61244 
2021-09-27
2021-06-30-1.41-0.70.7150 
2021-03-31
2020-12-310-1.2061-1.2061
2020-03-31
2019-12-310-0.7437-0.7437

About Dermata Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Dermata Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Dermata Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Dermata Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-25.3 M-27.3 M
Earning Before Interest and Taxes EBIT-3.5 M-3.8 M
Earnings per Basic Share(1.94) (2.09) 
Earnings per Diluted Share(1.94) (2.09) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-3.5 M-3.8 M
Earnings before Tax-3.7 M-4 M
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company was founded in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dermata Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Pair Trading with Dermata Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Dermata Therapeutics Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Dermata Therapeutics and Brickell Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Investing Opportunities. Note that the Dermata Therapeutics information on this page should be used as a complementary analysis to other Dermata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Dermata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.